Diverse mechanisms of mTOR activation in chronic and blastic phase of chronic myelogenous leukemia

Experimental Hematology

Volumn 41, Issue 5, 2013, Pages 462-469

  Stoklosa, Tomasz ^a   Glodkowska Mrowka, Eliza ^a   Hoser, Grazyna ^b   Kielak, Magdalena ^a   Seferynska, Ilona ^c   Wlodarski, Pawel ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

^c INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; RAPAMYCIN;

ARTICLE; BLAST CELL CRISIS; CELL COUNT; CELL DIFFERENTIATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA STEM CELL; PRIORITY JOURNAL; STEM CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; BLAST CRISIS; BLOTTING, WESTERN; CELL LINE; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLOW CYTOMETRY; FUSION PROTEINS, BCR-ABL; HUMANS; K562 CELLS; LEUKEMIA, MYELOID, CHRONIC-PHASE; NEOPLASTIC STEM CELLS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED;

MAMMALIA;

EID: 84876832386     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2013.02.001     Document Type: Article

References (46)

1. Nowell P.C., Hungerford D.A. A minute chromosome in human granulocytic leukemia. Science 1960, 132:1497-1498.
2. Rowley J.D. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973, 243:290-293.
3. Hochhaus A., Kreil S., Corbin A.S., et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002, 16:2190-2196.
4. Roche-Lestienne C., Soenen-Cornu V., Grardel-Duflos N., et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002, 100:1014-1018.
5. Ross D.M., Hughes T.P., Melo J.V. Do we have to kill the last CML cell?. Leukemia 2011, 25:193-200.
6. Skorski T. Chronic myeloid leukemia cells refractory/resistant to tyrosine kinase inhibitors are genetically unstable and may cause relapse and malignant progression to the terminal disease state. Leuk Lymphoma 2011, 52(Suppl 1):23-29.
7. Sillaber C., Mayerhofer M., Bohm A., et al. Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia. Eur J Clin Invest 2008, 38:43-52.
8. Teachey D.T., Grupp S.A., Brown V.I. Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br J Haematol 2009, 145:569-580.
9. Petroulakis E., Mamane Y., Le Bacquer O., Shahbazian D., Sonenberg N. mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer 2006, 94:195-199.
10. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22.
11. Drakos E., Rassidakis G.Z., Medeiros L.J. Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas. Expert Rev Mol Med 2008, 10:e4.
12. Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004, 18:1926-1945.
13. Steelman L.S., Franklin R.A., Abrams S.L., et al. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia 2011, 25:1080-1094.
14. Laplante M., Sabatini D.M. mTOR signaling at a glance. J Cell Sci 2009, 122:3589-3594.
15. Mamane Y., Petroulakis E., LeBacquer O., Sonenberg N. mTOR, translation initiation and cancer. Oncogene 2006, 25:6416-6422.
16. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
17. Sarbassov D.D., Ali S.M., Sengupta S., et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006, 22:159-168.
18. Chow S., Minden M.D., Hedley D.W. Constitutive phosphorylation of the S6 ribosomal protein via mTOR and ERK signaling in the peripheral blasts of acute leukemia patients. Exp Hematol 2006, 34:1183-1191.
19. Haritunians T., Mori A., O'Kelly J., Luong Q.T., Giles F.J., Koeffler H.P. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 2007, 21:333-339.
20. Ly C., Arechiga A.F., Melo J.V., Walsh C.M., Ong S.T. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Res 2003, 63:5716-5722.
21. McCubrey J.A., Steelman L.S., Abrams S.L., et al. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 2008, 22:708-722.
22. Burchert A., Wang Y., Cai D., et al. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia 2005, 19:1774-1782.
23. Skorski T., Nieborowska-Skorska M., Wlodarski P., et al. The SH3 domain contributes to BCR/ABL-dependent leukemogenesis in vivo: role in adhesion, invasion, and homing. Blood 1998, 91:406-418.
24. Konig H., Copland M., Chu S., Jove R., Holyoake T.L., Bhatia R. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells. Cancer Res 2008, 68:9624-9633.
25. Mizuchi D., Kurosu T., Kida A., et al. BCR/ABL activates Rap1 and B-Raf to stimulate the MEK/Erk signaling pathway in hematopoietic cells. Biochem Biophys Res Commun 2005, 326:645-651.
26. Perrotti D., Jamieson C., Goldman J., Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest 2010, 120:2254-2264.
27. Bhaskar P.T., Hay N. The two TORCs and Akt. Dev Cell 2007, 12:487-502.
28. Carracedo A., Baselga J., Pandolfi P.P. Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors. Cell Cycle 2008, 7:3805-3809.
29. Dengler J., von Bubnoff N., Decker T., Peschel C., Duyster J. Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib. Leukemia 2005, 19:1835-1838.
30. Corbin A.S., Agarwal A., Loriaux M., Cortes J., Deininger M.W., Druker B.J. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011, 121:396-409.
31. Eisterer W., Jiang X., Christ O., et al. Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease. Leukemia 2005, 19:435-441.
32. Diamond J.M., Melo J.V. Mechanisms of resistance to BCR-ABL kinase inhibitors. Leuk Lymphoma 2011, 52(Suppl 1):12-22.
33. Tauchi T., Ohyashiki K. Imatinib mesylate in combination with other chemotherapeutic agents for chronic myelogenous leukemia. Int J Hematol 2004, 79:434-440.
34. Calabretta B., Salomoni P. Inhibition of autophagy: A new strategy to enhance sensitivity of chronic myeloid leukemia stem cells to tyrosine kinase inhibitors. Leuk Lymphoma 2011, 52(Suppl 1):54-59.
35. Cortes J., Jabbour E., Daley G.Q., et al. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. Cancer 2007, 110:1295-1302.
36. Daley G.Q. Towards combination target-directed chemotherapy for chronic myeloid leukemia: Role of farnesyl transferase inhibitors. Semin Hematol 2003, 40:11-14.
37. Weisberg E., Banerji L., Wright R.D., et al. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Blood 2008, 111:3723-3734.
38. Hirase C., Maeda Y., Takai S., Kanamaru A. Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: Possible clinical application of mTOR inhibitor. Leuk Res 2009, 33:450-459.
39. Quentmeier H., Eberth S., Romani J., Zaborski M., Drexler H.G. BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance. J Hematol Oncol 2011, 4:6.
40. Weichhart T., Saemann M.D. The multiple facets of mTOR in immunity. Trends Immunol 2009, 30:218-226.
41. Pellicano F., Simara P., Sinclair A., et al. The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells. Leukemia 2011, 25:1159-1167.
42. Yu C., Krystal G., Varticovksi L., et al. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res 2002, 62:188-199.
43. Jiang X., Zhao Y., Smith C., et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007, 21:926-935.
44. Nieborowska-Skorska M., Kopinski P.K., Ray R., et al. Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood 2012, 119:4253-4263.
45. Mancini M., Corradi V., Petta S., Martinelli G., Barbieri E., Santucci M.A. mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein. Leuk Res 2010, 34:641-648.
46. Foster D.A., Toschi A. Targeting mTOR with rapamycin: One dose does not fit all. Cell Cycle 2009, 8:1026-1029.